Dishman Pharma Zooms 20% As US FDA Approves Its Cancer Drug


Dishman Pharmaceutical & Chemicals in Tuesday's pre-opening session is sizzling on the bourses, and the stock is up by 20% at Rs 278.70, as the company received US FDA approved cancer drug, Zejula for Tesaro Inc.

Dishman Pharmaceutical & Chemicals is one of the API suppliers of Zejula capsules. The stock hit its 52-week high of Rs 278.20, and is locked at its upper circuit in pre-opening session on Tuesday. The stock on the BSE witnessed huge spurt in volume by more than 1.53 times.

The stock on the NSE has delivered over 43% returns in a period of one year, and has outperformed the BSE Small-cap and BSE Healthcare indices over the same time span.

Dishman Pharmaceuticals and Chemicals Limited operates as an outsourcing partner for the pharmaceutical industry. The company manufactures and supplies intermediates, fine chemicals and various products for pharmaceutical, cosmetic and related industries.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: